

**Lionel PERRIER****PERSONAL DATA**

*Address* Cancer Centre Léon Bérard  
Clinical Research and Innovation Direction  
28 rue Laënnec  
69373 Lyon Cedex 08, France  
*Phone:*+33 (0) 478 78 29 08  
*Phone (assistant):*+33 (0) 4 69 85 61 00  
*Fax:* +33 (0) 478 78 59 45  
[lionel.perrier@lyon.unicancer.fr](mailto:lionel.perrier@lyon.unicancer.fr)

*Date of birth* July 25, 1968  
*Place of birth* Villefranche sur Saône (France)  
*Citizenship* French  
*Marital status* Married, two children Sébastien and Julie  
*Personal page* <http://www.gate.cnrs.fr/spip.php?article40>  
*ORCID iD* [orcid.org/0000-0003-4487-8723](http://orcid.org/0000-0003-4487-8723)

**POSITIONS HELD**

**Manager Innovations and Strategies**, Clinical Research and Innovation Direction (DRCI), Cancer Centre Léon Bérard, Lyon, France (*since 2014*)  
**Member of the Commission for Economic Evaluation and Public Health** (Commission Evaluation Economique et Santé Publique), French National Authority for Health (*since January 2015*)  
**Lecturer**, University of Lyon, France (*since 1998*) and Ecole Centrale of Lyon, France (*since 2014*)  
**Member of the GATE L-SE, UMR-CNRS 5824**, University of Lyon, France (*since 1998*)  
**Affiliated researcher**, Hospinnomics chair (Paris School of Economics, Assistance Publique - Hôpitaux de Paris, *since September 2015*)  
**Engineer-economist**, Cancer Centre Léon Bérard, Lyon, France (*from 2010 to 2014*)  
**Health economist**, Cancer Centre Léon Bérard, Lyon, France (*from 2001 to 2010*)

**EDUCATION**

**Accreditation to supervise doctoral research (HDR)**, University Lumière Lyon 2, France

*Title* Costs and financing of hospital care: applications to oncology

*Date of award* January 29, 2010

*Committee members* Prof. Giuseppe Mastrangelo (University of Padova, Italy) - President of the committee  
Prof. Gérard de Pouvourville (ESSEC Business School Paris, France) - referee  
Prof. Lise Rochaix (French National Authority for Health) - referee  
Prof. Jean-Louis Rullière (University Lumière Lyon 2, France) - referee  
Prof. Thierry Philip (University Claude Bernard Lyon 1, France)  
Dr Patrick Sylvestre-Baron (University Lumière Lyon 2, France)

**Ph.D. in Economics**, University Lumière Lyon 2, France

*Title* Financing of hospital care and optimal patient's trajectory in paediatric oncology

*Date of award* December 14, 2001

*Committee members* Prof. Gérard Duru (University Claude Bernard Lyon 1, France) – President of the committee  
Prof. Gérard de Pouvourville (ESSEC Business School Paris, France)- referee  
Prof. Marie-Odile Carrère (University Claude Bernard Lyon 1, France) - referee  
Prof. Thierry Philip (University Claude Bernard Lyon 1, France)  
Dr Patrick Sylvestre-Baron (University Lumière Lyon 2, France)  
Dr Marie-Claire Villeval (University Lumière Lyon 2, France)

*1999-2001* Doctoral studies in GATE, UMR-CNRS 5824, Cancer Centre Léon Bérard, 28 rue Laënnec, 69373 Lyon Cedex 08, France

*1996* Master of sciences 2 in Economics, University Lumière Lyon 2, France

*1995* Master of sciences 1 in Economics, Lumière Lyon 2 University, France

*1994* Bachelor in Economics, Lumière Lyon 2 University, France

**LANGUAGES** French (native); English and German (fluent); Spanish (basic level)  
Zertifikat Deutsch als Fremdsprache, Goethe Institut, Lyon, France (1994)

**RESEARCH TOPICS** Health economics assessment in oncology, financing of care, quality of life, health care systems and reforms

**RESEARCH PROJECTS (since 2009 with grant supports)**

**Evaluation of the very high sequencing platform built by the AURAGEN Consortium (mise en oeuvre et l'évaluation de projets pilotes de plateformes de séquençage très haut débit à visée sanitaire)**

Project leaders: Pr Jean-Yves Blay, Hassan Serrier, Ph.D., Pr Xiaolan Xie, Lionel Perrier, Ph.D.

Ministry of Health (DGOS), AAP Plan France Génomique 2017

**Place de l'acide ZOledronique dans la prise en charge par radiothérapie STERéotaxique des métastases vertébrales : Etude médico-économique de phase III, randomisée, contrôlée, en double aveugle contre placebo**

Project leaders: Dr Stéphane Supiot, M.D., Lionel Perrier, Ph.D.

Ministry of Health (DGOS) and the French National Cancer Institute (INCa), AAP PRME 2017

**Erectile dysfunction in low-risk prostate cancer: a phase III medico-economic study comparing brachytherapy to stereotactic body radiotherapy**

Project leaders: Pr Renaud de Crevoisier, Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP PRME 2016

**Economic evaluation of Extracranial stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with  $\leq 3$  bone-only metastasis a phase III medico-economic study comparing brachytherapy to stereotactic body radiotherapy**

Project leaders: Sébastien Thureau, M.D., Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP PHRC-K 2016

**Modélisation de l'aide informelle : approches économiques et applications au dispositif innovant d'accompagnement et de répit des aidants de la métropole de Lyon**

Project leader: Lionel Perrier, Ph.D.

AAP Handicap et perte d'autonomie, session 7 (IRESP), 2016

**Health economics evaluation of the adaptive radiotherapy strategy to decrease xerostomia in locally advanced oropharynx carcinoma**

Project leaders: Pr Renaud de Crevoisier, Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP PRME-K 2014

**Optimisation of disease management in patients with epithelial ovarian/fallopian tube/primary peritoneal carcinoma in France**

Project leaders: Pr Isabelle Ray-Coquard, Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP PRME-K 2014

**Economic impact of Next-generation sequencing (NGS) technologies**

Project leaders: Isabelle Borget Ph.D., Sandrine Baffert Ph.D., and Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP NGS, 2014

**Health economics evaluation of percutaneous vertebroplasty compared to radiation therapy in patients with painful spine metastases**

Project leaders: Bertrand Richioud, M.D., Lionel Perrier, Ph.D.

French National Cancer Institute (INCa), AAP PRME-K, 2013

**Health information system evaluation**

Project leader: Lionel Perrier, Ph.D.

Ministry of Health (DGOS), AAP PREPS, 2012

**Economic evaluation of a second opinion in sarcoma, GIST, and desmoid tumour treatments**

Project leaders: Lionel Perrier, Ph.D.; Jean-Michel Coindre, MD, PhD.

French National Cancer Institute (INCa), 2012

**Economic evaluation of program for a healthy diet and adequate physical activity for patients with breast cancer**

Project leaders: Lionel Perrier, Ph.D.; Béatrice Fervers, MD, PhD.

French National Cancer Institute, Fondation de France, Ligue du Rhône, Cancéropole Auvergne Rhône-Alpes (CLARA), 2010

**Costs analysis of volumetric arc modulation with RapidArc for head and neck cancer**

Project leaders: Lionel Perrier, Ph.D.; Pascal Pommier MD, PhD.

French National Cancer Institute (INCa), 2010

**Economic evaluation of stereotactic radiotherapy in non small cell lung cancer**

Project leaders: Lionel Perrier, Ph.D.; Pascal Pommier MD, PhD.; Claude Line MD.

French National Cancer Institute (INCa), 2010

**Economic evaluation of therapeutic patient education program applied to the management of chemotherapy treatment**

Project leaders: Lionel Perrier, Ph.D.; Catherine Sebban, MD.

Cancéropole Auvergne Rhône-Alpes (CLARA), 2010

**Long term economic consequences of variations in medical practices in the management of a rare tumour: soft tissue sarcoma in the Rhone-Alpes region**

Project leaders: Lionel Perrier, Ph.D.; Isabelle Ray-Coquard, MD., Ph.D.

Cancéropole Auvergne Rhône-Alpes (CLARA), 2010

**Cost effectiveness evaluation for treatment of sarcomas in two European Regions**

Project leaders: Lionel Perrier, Ph.D.; Isabelle Ray-Coquard, MD., Ph.D.

CONnective Tissue Cancers NETwork to integrate European Experience in Adult and Children (Network of Excellence funded by the 6th Framework Program of the European commission), Working package 4 “Epidemiology”, task 3 “medical practice”, (LSHC-CT-2005-018806), 2009

**PUBLICATIONS (since 2009)**

- **Perrier L.**, Rasclé P., Morelle M., Toulmonde M., Ranchere Vince D., Le Cesne A., Terrier P., Neuville A., Meeus P., Farsi F., Ducimetière F., Blay JY., Ray Coquard I., Coindre JM. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. *PLoS One*. 2018 Apr 5;13(4):e0193330.
- Morelle M., Plantier M., Dervaux B., Pagès A., Deniès F., Havet N., **Perrier L.**; French Costing Group. Methods for the analysis and treatment of cost data by micro- and gross-costing approaches. *Rev Epidemiol Sante Publique*. 2018 Mar;66 Suppl 2:S101-S118.
- **Perrier L.**; French Costing Group. Editorial. *Rev Epidemiol Sante Publique*. 2018 Mar;66 Suppl 2:S63-S64.
- Marino P., Touzani R., **Perrier L.**, Rouleau E., Kossi DS., Zou Z., Charrier N., Goardon N., Preudhomme C., Durand-Zaleski I., Borget I., Baffert S. Cost of cancer diagnosis using Next-Generation Sequencing targeted gene panels in routine practice : a nationwide French study. *European Journal of Human Genetics*. 2018 Mar ;26(3):314-323.

- Bibault JE., Morelle M., Huguet M., **Perrier L.**, Giraud P. In reply to Jean-François Daisne, Sandra Nuyts, Frédéric Duprez and Benoît Bihin. *International Journal of Radiation Oncology - Biology - Physics*, 2018 Mar 1 ;100(3):808-809.
- Bibault JE., Morelle M., Huguet M., Perrier L., Giraud P. In reply to Tallet et al. *International Journal of Radiation Oncology - Biology - Physics*, 2018 Feb 1 ;100(2):529-530.
- Huguet M., **Perrier L.**, Bally O., Benayoun D., De Saint Hilaire P., Beal Ardisson D., Morelle M., Havet N., Joutard X., Meeus P., Gabelle P., Provençal J., Chauleur C., Glehen O., Charreton A., Farsi F., Ray-Coquard I. Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. *BMC Health Serv Res*. 2018 Jan 4 ;18(1):3.
- Pérol O., Charbotel B., **Perrier L.**, Bonnand S., Belladame E., Avrillon V., Rebattu P., Gomez F., Lauridant G., Pérol M., Fervers B. Systematic Screening for Occupational Exposures in Lung Cancer Patients : A Prospective French Cohort. *Int J Environ Res Public Health*. 2018 Jan 4 ;15(1).
- Gnep K., Lizée T., Campillo-Gimenez B., Delpon G., Droupy S., **Perrier L.**, de Crevoisier R. Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers. *Cancer Radiother*. 2017 Oct ;21(6-7):478-490.
- Bibault JE., Dussart S., Pommier P., Morelle M., Huguet M., Boisselier P., Coche-Dequeant B., Alfonsi M., Bardet E., Rives M., Calugaru V., Chajon E., Noel G., Mecerlem H., Servagi Vernat S., **Perrier L.**, Giraud P. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer : A Propensity Score-Weighted Analysis. *Int J Radiat Oncol Biol Phys*. 2017 Jun 27.
- Penel-Page M., Marec-Bérard P., Morelle M., Bertrand A., Riberon C., Boyle H., **Perrier L.** Management of Febrile Neutropenias in Adolescents and Young Adults : A Cost-Minimization Analysis Between Adult Versus Pediatric Units. *J Adolesc Young Adult Oncol*. 2017 Jul 5.
- Rejeb O., Pilet C., Hamana S., Xie X., Durand T., Aloui S., Doly A., Biron P., **Perrier L.**, Augusto V. Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation. *Health Care Manag Sci*. 2017 May.
- Plantier M., Havet N., Durand T., Caquot N., Amaz C., Philip I., Biron P., **Perrier L.** Does adoption of electronic health records improve the quality of care management in France? Results from the French e-SI (PREPS-SIPS) study. *International Journal of Medical Informatics*. 2017 Jun;102:156-165.
- Varin M., Charbotel B., Pérol O., **Perrier L.**, Massardier-Pilonchéry A., Bonnand S, Belladame E., Fort E., Avrillon V., Rebattu P., Pérol M., Fervers B. Assessment of a self-administered questionnaire identifying occupational exposures among lung cancer patients. *Bull Cancer*. 2017 Jun;104(6):559-564.
- Havet N., Penot A., Morelle M., **Perrier L.**, Charbotel B., Fervers B. Trends in occupational disparities for exposure to carcinogenic, mutagenic and reprotoxic chemicals in France 2003-10. *Eur J Public Health*. 2017 Jun 1;27(3):425-432.
- Sambou C, Guillemaut S, Morelle M, Achache A, Le Corroller AG, Perol D, **Perrier L.** ISO 9001 certification of innovation and clinical research departments: Extending the scope of health assessment. *Rev Epidemiol Sante Publique*. 2017 Apr;65(2):159-167.
- **Perrier L.**, Morelle M., Huguet M., Dussart D., Giraud P.. In Reply to Escande et al. *International Journal of Radiation Oncology • Biology • Physics*. 2017. Vol. 97, Issue 1, p205–208.
- Plantier M., Havet N., Durand T., Caquot N., Amaz C., Philip I., Biron P., **Perrier L.** Does adoption of electronic health records improve organizational performances of hospital surgical units? Results from the French e-SI (PREPS-SIPS) study. *International Journal of Medical Informatics*. 2017 Feb;98:47-55.
- Havet N, Penot A, Morelle M, **Perrier L.**, Charbotel B, Fervers B. Varied exposure to carcinogenic, mutagenic, and reprotoxic (CMR) chemicals in occupational settings in France. *Int Arch Occup Environ Health*. 2017 Feb;90(2):227-241.

- Ceraulo A, Ouziel A, Lavergne E, **Perrier L**, Decouvelaere AV, Chotel F, Thiesse P, Marec-Berard P. Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients: a safe, accurate, and cost-saving procedure. *Pediatr Radiol*. 2017 Feb;47(2):235-244.
- Defourny N., Dunscombe P., **Perrier L.**, Grau C, Lievens Y. Cost evaluations of radiotherapy: what do we know? An ESTRO-HERO analysis. *Radiotherapy and Oncology*. 2016. 121(3):468-474.
- **Perrier L.**, Morelle M., Dussart D., Giraud P. In Reply to Fodor and Di Muzio. *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):1124-1126.
- Silva ML., Paget JW., Mosnier A., Buthion V, Cohen JM., **Perrier L.**, Späth HM. *Value Health*. 2016 Jul-Aug;19(5):670-9.
- Bibault JE., Morelle M., **Perrier L.**, Pommier P., Boisselier P., Coche-Dequéant B., Gallocher O., Alfonsi M., Bardet É., Rives M., Calugaru V., Chajon E., Noël G., Mecellem H., Pérol D., Dussart S., Giraud P. *Cancer Radiother*. 2016 Jul;20(5):357-61.
- **Perrier L.**, Morelle M., Pommier P., Boisselier P., Coche-Dequeant B., Gallocher O., Alfonsi M., Bardet E., Rives M., Calugaru V., Chajon E., Noel G., Mecellem H., Pérol D., Dussart S., Giraud P. (2016). Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer. *Int J Radiat Oncol Biol Phys*. 1;95(2):654-62.
- Poullié AI., Cognet M., Gauthier A., Clementz M., Druais S., Späth HM., **Perrier L.**, Scemama O., Pichon CR., Harousseau JL. (2016). Cost-effectiveness of treatments for mild to moderate obstructive sleep apnea in France. *Int J Technol Assess Health Care*. Mar 9:1-9.
- Silva ML., **Perrier L.**, Paget WJ., Mosnier A., Buthion V. Cohen JM., Späth HM. (2016) The decision-making process regarding national influenza vaccination recommendations: interactions of stakeholders in two european countries. *Health Policy*. 120(3):293-305.
- Buja A., Martines D., Lobello S., **Perrier L.**, Vinelli A., Bardelle G., Lopatriello S., De Lazzari F., **Perrier L.**, Balbo V. (2015) A cost-consequence analysis of hepatitis B screening in an immigrant population. *Annali dell'Istituto Superiore di Sanità*. 51(5):327-335.
- Silva ML., **Perrier L.**, Cohen JM., Paget WJ., Mosnier A., Späth HM. (2015) A literature review to identify factors that determine policies for influenza vaccination. *Health Policy*. 119(6):697-708.
- **Perrier L.**, Buja A., Mastrangelo G., Sylvestre Baron P., Ducimetière F., Pauwels P., Rossi CR., Gilly FN., Martin A, Favier B., Farsi F, Laramas M., Baldo V., Collard O., Cellier D., Blay JY., Ray-Coquard I. (2014) Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. *BMC Health Serv Res*. Nov 18;14(1):537.
- Havet N., Penot A., Morelle M., **Perrier L.**, Fervers B. (2014) Inégalités d'exposition aux agents cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France. *Environnement, Risque, Santé*. 13 (8)4: 336-341.
- Cox DG., Ragusa S., Pourtau L., **Perrier L.**, Delalogue S. (2014) Cost-effectiveness of a Genetic Test for Breast Cancer Risk – Letter. *Cancer Prev Res (Phila)*. Feb 5.
- Silva ML., **Perrier L.**, Späth HM., Grog I, Mosnier A., Havet N., Cohen JM. (2014). Economic burden of seasonal influenza B in France during winter 2010-2011. *BMC Public Health*. 14(1):56.
- Touillaud M., Foucaut AM., Berthouze SE., Reynes E., Kempf-Lépine AS., Carretier J., Pérol D., Guillemaut S., Chabaud S., Bourne-Branchu V., **Perrier L.**, Trédan O., Fervers B., Bachmann P. (2013). Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study. *BMJ Open*. 28(10): e003855.

- Pommier P, Morelle M, Millet-Lagarde F, Peiffert D, Gomez F, **Perrier L.** (2013). Curiethérapie : valorisation et aspects médico-économiques [Valorisation of brachytherapy and medico-economic considerations]. *Cancer Radiother.* 17(2):178-81.
- **Perrier L.**, Lefranc A., Pérol D., Quittet P., Schmidt-Tanguy A., Siani C., de Peretti C., Favier B., Biron P., Moreau P., Bay JO., Lissandre S. Jardin F., Espinouse D., Sebban C. (2013). Cost-effectiveness of pegfilgrastim versus filgrastim after high dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: An economic evaluation of the PALM trial. *Appl Health Econ Health Policy.* 11 (2):129–138.
- **Perrier L.**, Morelle M., Pommier P., Lagrange JL., Laplanche A., Dudouet P., Mahé M., Chauvet B., Nguyen TD., Créhange G., Beckendorf V., Pene F., Muracciole X., Bachaud JM., de Crevoisier R. (2013). Cost of prostate Image-Guided Radiation Therapy: results from a randomized trial. *Radiother Oncol.* 106 (1) :50-58.
- Silva ML., Mounjid N., **Perrier L.**, Späth HM. (2012). The use of economic evaluations in health decision-making at the macro level: a literature review. *Journal de gestion et d'économie médicales.* 30 (4) : 231-251.
- Pommier P., Morelle M., **Perrier L.**, de Crevoisier R., Laplanche A., Dudouet P., Mahé MA., Chauvet B., Nguyen TD., Créhange G., Zawadi A., Chapet O., Latorzeff I., Bossi A., Beckendorf V., Touboul E., Muracciole X., Bachaud JM., Supiot S., Lagrange JL.(2012). Evaluation économique prospective de la radiothérapie guidée par l'image des cancers de la prostate dans le cadre du programme national de Soutien aux Thérapeutiques Innovantes et Coûteuses [Prospective economic evaluation of image-guided radiation therapy for prostate cancer in the framework of the national programme for innovative and costly therapies assessment]. *Cancer Radiother.* 16(5-6):444-51.
- **Perrier L.**, Buja A., Mastrangelo G., Vecchiato A., Sandona P., Ducimetiere F., Blay J.Y., Gilly F.N., Siani C., Biron P., Ranchere-Vince D., Decouvelaere A.V., Thiesse P., Bergeron C., Dei Tos A.P., Coindre J.M., Rossi C.R., Ray-Coquard I.(2012). Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. *BMC Health Serv Res.* Mar 28;12(1):82.
- Sebban C., Lefranc A., **Perrier L.**, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P. (2012). A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). *Eur J Cancer.* 48(5):713-20.
- **Perrier L.**, Morelle M, Havet N, Montella A, Favier B, Pérol D, Gomez F, Rebattu P. (2010). Impact of chemotherapy prescriptions and costs on survival in advanced or metastatic NSCLC: a single-institution study using an instrumental variables approach. *Journal d'Économie Médicale;* 28;8:295-310.
- **Perrier L.**, Philip T. (2010). Apports de l'évaluation économique et de l'analyse d'impact budgétaire pour la décision publique en santé : l'exemple du cancer du sein [Contribution of economic evaluation and budget impact analysis to public decision in health: the example of breast cancer]. *Bulletin du Cancer;* 97;3:397-402.
- **Perrier L.**, Philip T. (2009). Le cancer du sein dans le budget de la nation [The breast cancer in the budget of the Nation], in *Un cancer du sein aujourd'hui et demain.* Courbevoie: Edition Datebe, p. 94-95.
- **Perrier L.**, Cautela N., Morelle M., Havet N., Ducimetière F., Lurkin A., Blay J-Y., Biron P., Ranchère-Vince D., Decouvelaere A-V., Thiesse P., Bergeron C., Gilly F., de Laroche G., Cellier D., Laramas M., Philip T., Ray-Coquard I. (2009). Costs and compliance with clinical practice guidelines: A pilot study for initial sarcoma treatment. *Journal d'Economie Médicale;* 27;5:307-327.
- **Perrier L.**, Pommier P., Carrère M-O., Sylvestre Baron P. (2009). Transférabilité des évaluations de coûts en santé : analyse des facteurs de variabilité [Transferability of cost assessment in health care: analyse of variability factors]. *Revue Economique;* 60;2:307-322.

## COMMUNICATIONS AND PARTICIPATION IN CONFERENCES (since 2009)

### **Les impacts médico-économiques de l'évolution du parcours de soins en cancérologie**

*15<sup>ème</sup> journée annuelle du réseau ONCOCENTRE*

*7 December 2017, Escale St Cyr sur Loire*

### **Radiotherapy costs: the good, the bad and the ugly**

*European Society for Radiotherapy & Oncology (ESTRO)*

*5 - 9 May 2017, Vienna, Austria*

### **Why should we focus on a structured model of secure digital exchanges to incorporate new documents in electronic patient records ?**

*19th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value in Health, vol 19, number 7 page A629)*

*Vienna, Austria, 29 October-2 November 2016*

### **Is the integrated electronic health record cost-effective for a cancer consultation ? » Results from the E-SI (Preps-Sips) Study**

*19th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value in Health, vol 19, number 7 page A735)*

*Vienna, Austria, 29 October-2 November 2016*

### **Nouvelles molécules, révolution thérapeutique, maîtrises des dépenses : Comment concilier innovation et accessibilité ?**

*Plateau débat, 6ème Université d'été, Agence Nationale d'Appui à la Performance des établissements de santé et médico-sociaux (ANAP), Lyon, France, 2 septembre 2016*

### **A cost-effectiveness analysis of the ZIRA test in breast cancer**

*21th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value in Health, vol 19, number 3, page A303)*

*Hilton, Washington DC, USA, 16-20 May 2016*

### **A cost-effectiveness analysis of a 6-month physical activity program versus usual dietary care during adjuvant chemotherapy in breast cancer: An economic evaluation of the PASAPAS trial.**

*21th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value in Health, vol 19, number 3, page A149)*

*Hilton, Washington DC, USA, 16-20 May 2016*

### **Impact of health information systems on hospital bed occupancy rates in French hospitals: results from the e-SI (PREPS-SIPS) study**

*21th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value in Health, vol 19, number 3, page A273)*

*Hilton, Washington DC, USA, 16-20 May 2016*

### **Cost of genome analysis: The Sanger sequencing method of questionnaire-based process to identify occupational exposures among patients with lung cancer**

*18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value Health. 2015 Nov;18(7):A353)*

*MIMO, Milan, Italy, 10-13 November 2015*

### **Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer**

*18th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation (Value Health. 2015 Nov;18(7):A485)*

*MIMO, Milan, Italy, 10-13 November 2015*

### **Relationship between the implementation of health information systems and the activity per surgeon and operating room usage in France: results from the E-SI (PREPS-SIPS) study**

*European Telemedicine Conference*

*Oral presentation (International Journal of Integrated Care (IJIC), Vol 15, ETC Conference Supplement 2015)*

*Congress Centre, Odense, Denmark, 21-22 October 2015*

**Health information system adoption and hospital accreditation in France : Results from the e-SIS (PREPS-SIPS) study**  
*11th World Congress of the international Health Economics Association (iHEA)*  
*Oral presentation*  
*Bocconi University, Milan, Italy, 12-15 July 2015*

**Système d'Information de santé**  
*3ème Journée Interrégionale des Systèmes d'Information en Santé*  
*Guest Speaker*  
*Faculté de médecine, Clermont-Ferrand, France, 24 juin 2015*

**Relationship between the development of electronic health records and hospital accreditation decisions in France: Results from the e-SIS (PREPS-SIPS) study.**  
*20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster presentation (Value in Health, vol 18, number 3, page A86)*  
*Marriott Downtown, Philadelphia, USA, 16-20 May 2015*

**Evaluation médico-économique en milieu hospitalier**  
*7th Journée Régionale de la Recherche Clinique et des Innovations (J2RCI)*  
*Guest Speaker*  
*U.F.R. d'Odontologie, Clermont-Ferrand, France, 11 novembre 2014*

**Economic impact of centralized histological reviews in patients with sarcoma, GIST, and desmoid tumors**  
*17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster presentation (Value in Health, vol 17, number 7, page A624)*  
*RAI, Amsterdam, The Netherlands, 8-12 November 2014*

**A cost-analysis of complex radiotherapy in patients with head and neck cancer: results from the ART-ORL study**  
*17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster presentation (Value in Health, vol 17, number 7, page A624)*  
*RAI, Amsterdam, The Netherlands, 8-12 November 2014*

**Evaluation en Système d'Information de Santé : protocole d'étude**  
*7ème conférence de Gestion et Ingénierie des Systèmes Hospitaliers (GISEH)*  
*Oral presentation*  
*University of Liège, Belgium, 7-9 July 2014*

**Cost of discordant diagnoses in sarcoma, GIST, and Desmoid tumors in France: results from the RREPS (Réseau de Référence en pathologie des sarcomes) network**  
*19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster presentation (Value in Health, vol 17, number 3, page A95-96)*  
*International Convention Centre, Montréal, Canada, 2-4 June 2014*

**Les fortes expositions aux produits cancérigènes, mutagènes ou reprotoxiques sont-elles l'apanage des emplois précaires ou peu qualifié**  
*4ème congrès national Cancer et Environnement,*  
*Oral presentation*  
*Hôtel de région, Lyon, France, 29 November 2013*

**A cost-analysis of stereotactic radiotherapy in lung cancer**  
*16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster presentation (Value in Health, vol 16, number 7, page A401)*  
*International Convention Centre, Dublin, Ireland, 2-6 November 2013*

**Understanding the use of health economics evaluation in France**  
*10<sup>ème</sup> journées annuelles du Groupe Sarcome Français (GSF-GETO)*  
*Oral communication*  
*Centre des congrès, Strasbourg, France, 26-28 June 2013*



**Evidence based medicine: Level of evidence**

*4<sup>ème</sup> journée nationale des innovations hospitalières*  
*Oral communication*  
*Faculté de Pharmacie, Nantes, France, 07 June 2013*

**Evaluation Cost of physical activity intervention during adjuvant chemotherapy in breast cancer: results of the randomized trial PASAPAS**

*8èmes journées scientifiques du CancéroPôle Lyon Auvergne Rhône-Alpes*  
*Poster (ref 042)*  
*Champfleuri, Lyon, France, 21-22 mars 2013*

**Evaluation économique d'une intervention nutritionnelle chez des patientes atteintes d'un cancer du sein : résultats d'une étude contrôlée randomisée**

*10èmes Journées Francophones de Nutrition*  
*Poster (ref 009)*  
*International Congress Centre, Lyon, France, 12-14 December 2012*

**Discordant diagnoses in sarcoma, GIST and desmoids tumour in France: Results from the network RREPS**

*15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Podium presentation (Value in Health, vol 15, number 7, page A285)*  
*International Congress Centre, Berlin, Germany, 3-7 November 2012*  
*APM International Mardi 6 novembre 2012 - 19:20 Diagnostic des sarcomes: une étude française valide l'importance d'une seconde opinion*

**A cost-analysis of Image Guided Radiation Therapy (IGRT) in prostate cancer: Results from a phase III clinical trial**

*15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster (Value in Health, vol 15, number 7, page A416)*  
*International Congress Centre, Berlin, Germany, 3-7 November 2012*

**Cluster analysis and principal component analysis to assess the variability of data in cost evaluations: methods and applications in oncology**

*15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster (Value in Health, vol 15, number 7, page A486)*  
*International Congress Centre, Berlin, Germany, 3-7 November 2012*

**Cost-effectiveness analysis: an interdisciplinary research and methodological perspective**

*Guest Speaker*  
*University degli Studi di Padova, Italy, July 19, 2012*

**Round table « Thérapies innovantes: lesquelles et à quel prix »?**

*with M. Volckmann (manager innovative therapy Europe Sanofi-Pasteur), M. Rousselle (manager PX Therapeutics), M. Pauwels (manager CLARA), M. Longera (Manager Merck Serono)*  
*Faculté de pharmacie, Université Claude Bernard Lyon 1, Lyon, 24 November 2011*

**Cost-effectiveness analysis of compliance with clinical practice guidelines in sarcoma treatment: an economic evaluation in two European regions**

*14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster (ref PCN 76)*  
*Hotel Auditorium, Madrid, Spain, November 5-8, 2011*

**Cost-effectiveness of granulocyte colony stimulating factor in primary and secondary prophylaxis of febrile neutropenia in patients with stages 2 and 3 breast cancer undergoing cytotoxic chemotherapy in France**

*14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*  
*Poster (ref PCN 77)*  
*Hotel Auditorium, Madrid, Spain, November 5-8, 2011*

**Economic model of granulocyte colony stimulating factor in primary and secondary prophylaxis of febrile neutropenia in non Hodgkin's lymphoma patients undergoing chemotherapy in France**

*14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster (ref PCN 88)*

*Hotel Auditorium, Madrid, Spain, November 5-8, 2011*

**Conformity with clinical practice guidelines for management of patients with sarcoma: a cost-effectiveness assessment in two European regions**

*16<sup>th</sup> annual conference of the Italian Health Economics Association (AIES)*

*Oral communication*

*Second university of Naples, Naples, Italy, September 29-30, 2011*

**Cancer treatment**

*8<sup>th</sup> World congress on Health Economics, International Health Economics Association*

*Session Chairman*

*Sheraton, Toronto, Canada, July 10-13, 2011*

**Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial**

*8<sup>th</sup> World congress on Health Economics, International Health Economics Association*

*Poster and short oral presentations (ref TO-P1576)*

*Sheraton, Toronto, Canada, July 10-13, 2011*

**Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma**

*16<sup>th</sup> Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research*

*Poster presentation PCN60, Value in Health, vol.14 (3), p. A165*

*Convention centre, Baltimore, USA, May 21-25, 2011*

**Costi del trattamento**

*Symposium Sarcomi delle parti molli e GIST: epidemiologia, clinica e "network"*

*Guest Speaker*

*Istituto oncologico Veneto, Padova, Italy, May 6, 2011*

**Cost-effectiveness analysis: methods and applications in oncology**

*Guest Speaker (introduction: Prof. Francesco Grigoletto Dipartimento di Medicina Ambientale Sanità Pubblica, Università di Padova; discussion: Prof Carlo Riccardo Rossi Dipartimento di Scienze Oncologiche e Chirurgiche and Dott.ssa Eva Pagano Servizio di Epidemiologia dei Tumori, Università di Torino e CPO Piemonte, ASO San Giovanni Battista di Torino)*

*Università degli Studi di Padova, Dipartimento di Medicina Ambientale e Sanità Pubblica & Dipartimento di Scienze Oncologiche e Chirurgiche, Padova, Italy, February 17, 2010*

**Cost-effectiveness of venous access devices: methods, and limited applicability**

*3<sup>rd</sup> Multidisciplinary advanced course on venous access, MACOVA*

*Guest Speaker*

*Congress Centre, Lyon, France, December 18, 2009*

**Cancer et Travail [Cancer and Work]**

*31<sup>th</sup> Journées des Economistes de la Santé Français*

*Session Chairman*

*ENSAI, Rennes, France*

*December 3-4, 2009*

**Cost-effectiveness analysis of compliance with clinical practice guidelines for sarcoma management**

*Work Package 4 "Epidemiology" meeting, CONnective TIssue CANcers NETwork*

*Guest Speaker*

*Bergonié Institute, Bordeaux, France, March 23-24, 2009*

## PhD THESIS SUPERVISION (since 2010)

**Wilfried Guets**, *Modélisation de l'aide informelle : approches économiques et applications au dispositif innovant d'accompagnement et de répit des aidants de la métropole de Lyon*, Lyon 2 University (since 2017)  
Funding: Institut de Recherche en Santé Publique (IReSP)

**Marius Huguet**, *Traitement du biais de sélection, estimation de l'effet causal et modélisation microéconomique : une application à la prise en charge des cancers de l'ovaire en France* (co-supervision with X. Joutard, Aix Marseille University), Lyon 2 University (since 2016)  
Funding: Lyon 2 University

**Noémie Defourny**, *The cost of Radiotherapy in Europe : what does it cost, and how can these data be used to support innovation in European radiotherapy practice ?* (co-supervision with Y. Lievens University of Gent), University of Gent, Belgium (since 2014)  
Funding: European Society for Radiotherapy & Oncology (ESTRO)

**Maria Laura Silva**, *The role of the economic evaluations in health decision making: an application to influenza vaccination*, Lyon 2 University (date of Defense 7th March 2016)  
Funding : Science sans frontières ; Current position: Associate Professor, University of Bordeaux

## PARTICIPATION AS REFEREE / EXTERNAL EXAMINER TO PhD THESES' DEFENSE

**Rana Maroun**, *Analyse comparative coût et efficacité des traitements du cancer du rein métastatique : analyse à partir des données de vie réelle et des données d'essais*, Paris-Saclay University, 2018 (referee)

**Omar Kanj**, *Evaluation économique de la prise en charge de l'endométriose*, University Clermont Auvergne, 2017 (referee)

**Sabri Hamana**, *Modélisation et simulation des flux d'informations ville-hôpital et de leur impact sur le parcours de soins*, Ecole Nationale des Mines de Saint-Etienne, 2017 (external examiner)

## TEACHING EXPERIENCE (since 2009)

**Cost-effectiveness analysis: methodology, applications, and perspective in environmental interventions (2013-2018)**  
Cours (6 hours), Master of sciences RISE, Ecole Centrale Lyon, France

**Evaluation des programmes de santé [Evaluation of health care programmes] (2017-2018)**  
Cours (21 hours), Master of sciences APE, University Lumière Lyon 2, France

**Evaluation des programmes de santé [Evaluation of health care programmes] (2009-2016)**  
Cours (21 hours), Master of sciences EQUADE, University Lumière Lyon 2, France

**Economie de la santé [Health economics] (2009-2016)**  
Cours (21 hours), Master of sciences E-QUANT, University Lumière Lyon 2, France

**Microéconomie appliquée [Applied microeconomics] (2009-2016)**  
Cours (15 hours), Bachelor of sciences, University Lumière Lyon 2, France

**La tarification à l'activité [The French DRG payment system] (2009-2010)**  
Seminar (3 hours), Master of sciences, University Claude Bernard Lyon 1, France

## EXPERTISES (since 2009)

### French National Health Authority (HAS)

Member of the Work Committee “*Evaluation clinique et économique des dispositifs médicaux et prestations associées pour prise en charge du syndrome d’apnée hypopnée obstructive du sommeil (SAHOS)*” French National Health Authority (Haute Autorité de Santé), 2013-2014

Member of the Work Committee “*Technique du ganglion sentinelle dans le cancer du sein*” [Sentinel lymph nodes in breast cancer], French National Health Authority (Haute Autorité de Santé) 2011

Member of the Work Committee “*Evaluation du dépistage de la rétinopathie diabétique par lecture différée de photographies du fond d’oeil*” [Evaluation of screening for diabetic retinopathy by deferred digital fundus photography], French National Health Authority (Haute Autorité de Santé), 2009-2010

Member of the Steering Committee of the clinical practice guideline “*Traitement médicamenteux du diabète de type 2*” [Drug treatment of type 2 diabetes], French National Health Authority (Haute Autorité de Santé), 2009

Member of the Review Committee “*Recommandation en santé publique: évaluation des stratégies de prévention de la carie dentaire*” [Public health recommendations and evaluation of strategies for the prevention of tooth decay], French National Health Authority (Haute Autorité de Santé), 2009

### French Ministry of Health

Member of the selection committee for grants “*Programme Hospitalier de Recherche Clinique (PHRC-N)*”, French Ministry of Health (since 2015)

Member of the selection committee for grants “*Programme de Recherche Médico-Economique (PRME-N)*”, French Ministry of Health (since 2013)

Member of the Steering Committee GT 4 Innovation, French National Committee of the clinical research and innovation (Assemblée nationale des délégations à la recherche clinique et à l’innovation), since 2012 and coordinator of the working group “*Costing methods*”

### National Cancer Institute (INCa)

Expert advisor for grants “*Human and social sciences, Epidemiology and Public Health*”, National Cancer Institute (INCa), since 2012

### ISPOR / iHEA

Member of the Milan 2015 iHEA Scientific Committee

Member of the Abstract Review Committee for the ISPOR International Meeting, since 2011

### Reviewing manuscript for peer-Review Journal

*Applied Clinical Informatics ; Applied Health Economics and Health Policy; BMC Pulmonary Medicine; BMC Medical Informatics and Decision Making ; the British Journal of Radiology; Expert Review of Pharmacoeconomics & Outcomes Research; European Journal of Cancer; The International Journal for Quality in Health Care; Lung cancer; Pharmacoeconomics; Sarcoma; Social Science and Medicine.*

*Critical analysis of the health ranking of the 36 cities over 100,000 inhabitants by the journal Impact Médecine and article published by Mr. Beaudouin “Grenoble in good health” Actors of the Rhone-Alps economy, 80, February 2009, pages 6-7*

### Others

Member of the Cortex project (LabEx), Investissements d’Avenir (ANR-11-IDEX-0007) since 2012

Member of the editorial advisory board of the Journal d’Economie Médicale Member of the board of the GATE LSE, UMR-CNRS 5824 (2007-2010 and 2011-2015)

Date: 09<sup>th</sup> April 2018

Signature

